Drugs / BI 831266
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00756223 | Nov 2008 → Oct 2010 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 831266 | “Phase I Study of BI 831266 in Patients With Advanced Solid Tumours” NCT00756223 ↗ |
| Action | Inhibit | “Aurora kinase B inhibitor” PMID 25529193 ↗ Dec 2014 |
| Route | Intravenous | “BI 831266 Administered Intravenously Over 24 h Continuously” NCT00756223 ↗ |
| Target | AURKB | “Aurora kinase B inhibitor” PMID 25529193 ↗ Dec 2014 |